Vancouver, BC -- (SBWIRE) -- 03/02/2015 -- DelMar Pharmaceuticals, Inc. (DMPI) (DelMar and the Company), a company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application number 13/817,096 entitled, "Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol."

The allowed patent claims cover DelMar's novel methods and compositions for the utility of chemical agents, compounds, and dosage forms related to administering VAL-083 (dianhydrogalactitol) for the treatment of hyperproliferative diseases, including cancer, to improve efficacy and reduce side effects of previously suboptimal chemotherapeutic agents.

"This is the very first patent application filed when we recognized the broad potential of VAL-083, a drug candidate that has demonstrated promising results in multiple cancer indications in previous clinical trials sponsored by the U.S. National Cancer Institute," commented Jeffrey Bacha, DelMar's president and CEO. "Importantly, this U.S. patent allowance is for a master set of claims covering uses and compositions for VAL-083 and is an integral part of DelMar's robust and comprehensive patent estate expansion strategy."

The USPTO issues a Notice of Allowance after it makes a determination that a claimed invention is novel and nonobvious in light of all known technology in existence, and that a patent should be granted from such an application. Based on the timing of this Notice of Allowance, DelMar Pharmaceuticals expects the forthcoming VAL-083 patent to be issued by mid-2015 and provide intellectual property protection for methods and compositions of use for VAL-083 through 2030.

Mr. Bacha added, "We are confident that we will continue to build upon our intellectual property portfolio designed to protect and enhance the value of VAL-083 as we prepare to advance towards U.S. registration trials in refractory glioblastoma multiforme and prepare to expand our clinical research into non-small cell lung cancer this year."

This is the second notice of allowance the Company received this year from the USPTO for patents covering VAL-083. Upon issuance, DelMar will hold four U.S. patents and one international patent for VAL-083, having filed a total of more than ten new patent applications, which are being prosecuted in the United States and in international jurisdictions.

About VAL-083
VAL-083 is a first-in-class, small-molecule chemotherapeutic with a unique mechanism of action. In more than 40 Phase 1 and 2 clinical trials sponsored by the U.S. National Cancer Institute, VAL-083 has shown safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and the United States for the treatment of gliomas. DelMar is currently studying VAL-083 in a Phase 1/2 clinical trial for patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of brain cancer. As a potential treatment for GBM, VAL-083's mechanism of action is unaffected by the expression of MGMT, a DNA repair enzyme that causes resistance to other chemotherapies approved for the treatment of GBM, including front-line treatment with Temodar® (temozolomide).

About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

For further information, please visit http://www.delmarpharma.com/; or contact Jeffrey A. Bacha, President & CEO 604-629-5989 or Amato & Partners LLC, Investor Relationsadmin@amatoandpartners.com. Follow us on Twitter @DelMarPharma or on Facebook Facebook.com/delmarpharma.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-receives-notice-of-allowance-of-fourth-us-patent-covering-methods-of-use-and-compositio

Source: UPTICK Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelMar Pharmaceuticals Presents Data at AACR’s New Horizons in Cancer Research Conference in Shanghai, China

Vancouver, BC -- (SBWIRE) -- 10/09/2014 -- DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai.

"The data presented today showed that VAL-083 is superior to cisplatin in both tumor models that are sensitive and resistant to tyrosine kinase inhibitorsand has synergistic effect in combination with cisplatin," said Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals. "This data suggests important clinical and market potential of VAL-083 innon-small cell lung cancer."

DelMar's lead clinical compound, VAL-083 (dianhydrogalactitol) is a first-in-class alkylating agent with a novel cytotoxic mechanism distinct from other alkylating agents used in the treatment of cancer.

In historical studies sponsored by the National Cancer Institute in the United States, VAL-083 exhibited clinical activity against a range of tumor types including CNS tumors, solid tumors and hematologic malignancies. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia (CML) and lung cancer (Approval No. Guoyao Zhunzi H45021133; manufactured by Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd.)

NSCLC is usually treated with either tyrosine kinase inhibitors (TKIs) (e.g. gefitinib) or platinum-based regimens (e.g. cisplatin). TKIs have resulted in vastly improved outcomes for patients with EGFR mutations; however, TKI resistance has emerged as a significant unmet medical need, and long-term prognosis with platinum-based therapies is poor. Compared to other countries, Asian patients with NSCLC have a higher incidence of EGFR mutations (up to 60 percent; compared to 10-20 percent in Western populations) and are more susceptible to TKI resistance.

Additionally, NSCLC patients have a high incidence of brain metastases, which is associated with a poor prognosis. The median overall survival time for patients with stage IV NSCLC is four months, while one-year and five-year survival is less than 16 percent and 2 percent, respectively. VAL-083 can cross the blood-brain barrier and is currently being evaluated in the United States in a Phase 1/2 clinical trial to treat the most common form of brain cancer, glioblastoma multiforme (GBM).

"Rates of lung cancer have been rising steeply over the past decade and are a significant public health problem in China," explained Mr. Bacha."China has one-third of the global deaths from lung cancer, and non-small cell lung cancer accounts for more than 85 percent of all lung cancer cases, of which almost half are diagnosed at an advanced stage of the disease. Because VAL-083 is already approved in China for the treatment of non-small cell lung cancer and has known activity in treating brain cancer, we have the potential to have a near-term option for doctors and millions of Chinese patients who today have not known this treatment was available."

DelMar's data presented at the AACR New Horizons in Cancer Research meeting seeks to answer three simple, fundamental questions:

-How does the activity of VAL-083 compare to standard platinum therapy?
-Can VAL-083 be combined with platinum based therapy?
-Can VAL-083 treat NSCLC that is resistant to platinum-based chemotherapy or TKIs?

In in vivo models of lung cancer, significant survival benefit was observed with VAL-083 in comparison to platinum-base chemotherapy in both TKI-susceptible (A549) and TKI-resistant (H1975) models of NSCLC. These observations suggest that VAL-083 maintains activity where cisplatin fails to gain a statistically significant benefit.

In a separate, standard model of anti-cancer activity, VAL-083 was superior to cisplatin in tumor growth delay. Interestingly, VAL-083 in combination with cisplatin produced a more than additive effect by delaying growth in vivo. These observations are supported by separate in vivo studies which reveal the potential for synergistic benefit for a combination of VAL-083 and platinum-based therapies against both TKI-susceptible (A549) and TKI-resistant (H1975) NSCLC tumor cell lines.

Taken together, the results suggest that VAL-083 is superior to cisplatin in both TKI-sensitive and resistant tumor models, has synergistic effect in combination with cisplatin, and suggest clinical potential in TKI-resistant NSCLC. This data provides direction to clinical research aimed at influencing practice patterns under VAL-083's current approval in China and support expanded global development.

"We believe these observations have important immediate implications in the treatment of NSCLC in China, where VAL-083 is approved for as chemotherapy for the treatment of lung cancer, and for future clinical development in the rest of the world," added Mr. Bacha. "Next steps include clinical validation of these promising results in a clinical study. Such work could be initiated in China in a post-approval setting."

Details of the company's presentation will be posted on DelMar's website under

http://www.delmarpharma.com/products/publications/

DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals are collaborating in the development of VAL-083 in China. DelMar is also this product in Phase I/II clinical trials in the United Stated as a potential treatment for refractory glioblastoma multiforme (clinicaltrials.gov identifier: NCT01478178).

About DelMar Pharmaceuticals
DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com; or contact Jeffrey A. Bacha, President & CEO (604) 629-5989 or Booke & Company Investor Relations, admin@bookeandco.com

UPTICK Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelMar Pharmaceuticals, Inc. is developing a new drug intended to treat various forms of cancer

Vancouver, BC -- (SBWIRE) -- 09/09/2014 -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) is developing a new drug intended to treat various forms of cancer, including a recurrent form of Brian Cancer, glioblastoma multiforme. The DelMar treatment VAL-083 is in Phase l/ll trials and showing promising results.

DelMar reported results of their ongoing clinical trial with VAL-083 at the annual meetings of both the American Association of Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). Data presented indicates that VAL-083 is safe, effective, and well tolerated. DelMar points out that some patients are already showing positive results, demonstrated stable disease, after only one or two cycles of low-dose treatment.

With these promising successes, DelMar has sought permission from the FDA to allow testing with increased dosage. The company believes that higher doses may enhance the potential of VAL-083 to impact a patient's tumor and improve patient outcomes.

Ultimately, DelMar believes advancing to higher doses will increase the chance of success in achieving the longer-term goal to commercialize VAL-083 as a new chemotherapy for glioblastoma patients, especially patients who have failed or are unlikely to respond, to currently available treatments.

Jeffrey Bacha, president and CEO of DelMar, stated, "Patients being enrolled in our current clinical trial have a growing brain tumor that has failed to respond to any other approved treatment. The correlation between tumor progression and death in this patient population is well documented; therefore, our interim results demonstrating that VAL-083 can either stabilize disease progression by halting tumor growth or shrink the tumor is expected to result in longer patient survival and improved quality of life. We anticipate enhanced response rates as we progress to higher doses and keep patients on treatment longer during future registration-directed clinical trials."

DelMar plans to advance clinical trials with VAL-083 as a potential treatment for GBM patients who have failed therapy with both Temodar® and Avastin®. Currently, there is no available or approved therapy for these patients and their prognosis is very poor, with a life expectancy of only weeks to months. DelMar is currently conducting a Phase I/II clinical trial at three centers: The Brain Tumor Center at University of California, San Francisco (UCSF), The Sarah Cannon Cancer Research Center (SCRI) in Nashville, Tenn., and the SCRI affiliate site at the Florida Cancer Specialist Research Institute in Sarasota, Fla. Details of the clinical trial can be found at:

http://www.delmarpharma.com/GBM_clinical_trial/

Mr. Bacha reiterated, "The goal of the current Phase I/II clinical trial is to reestablish the maximum tolerated dose of VAL-083 under our modernized dosing regimen for advancement into registration directed trials in the United States as a potential new therapy for the treatment of refractory GBM as soon as possible."

DelMar has received four nonrefundable grants from the National Research Council of Canada (NRC), totaling CDN $327,000, and DelMar Pharmaceuticals, Inc (OTCQB: DMPI) has also attracted the attention of long time Wall Street analyst, Jason Kolbert of Maxim Group.

DelMar will be presenting to prospective investors this week at Rodman Renshaw 2:55 pm EDT at the New York Plaza Hotel and the SeeThru Equity Microcap Conference at 11 am EDT at Convence Time Square, both in New York City

About DelMar Pharmaceuticals
DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute (NCI) and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action. DelMar's scientific presentations can be viewed on the company's website at http://www.delmarpharma.com.

http://www.upticknewswire.com

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit http://www.delmarpharma.com; or contact
Jeffrey A. Bacha, President & CEO (604) 629-5989 or Booke & Company Investor Relations, admin@bookeandco.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Delmar is pleased with the overall progress made during the past year in research and development activities

Vancouver, BC -- (SBWIRE) -- 08/29/2014 -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") today announced the filing of June 30, 2014 fiscal year-end financial statements. The Company recently changed its fiscal year end to June 30th in order to facilitate an application to list its common stock on a national securities exchange in the timeliest manner possible.

DelMar's financial statements as filed with the United States Securities Exchange Commission can be viewed on the company's website at: http://ir.delmarpharma.com/all-sec-filings. The company will host an investor update call to discuss recent highlights and plans for continued advancement of its business plan on Tuesday September 2, 2014 at 10AM PDT / 1PM EDT.

Dial In: (877) 358-8686 (toll free)
Passcode: 6043177022

A summary of recent corporate highlights include:

- Promising interim results of DelMar's ongoing clinical trial with VAL-083 were presented at the annual meetings of both the American Association of Cancer Research (AACR) in April and the American Society of Clinical Oncology (ASCO) in May. Data presented to date demonstrate that VAL-083 is safe and well tolerated at doses up to 40mg/m2. In addition, one of three patients in the 30mg/m2 dose cohort and one of three patients in the 40mg/m2 dose cohort demonstrated stable disease after only one or two cycles of treatment.

- On August 19, DelMar announced the filing of a protocol amendment with the United States Food and Drug Administration to allow enrollment at doses up to 60mg/m2 and that treatment of patients at 50mg/m2has been initiated. DelMar is now delivering higher doses compared to previous glioblastoma clinical trials conducted by the National Cancer Institutes in the United States. The company believes that such higher doses may enhance the potential of VAL-083 to impact a patent's tumor and improve patient outcomes. Ultimately, DelMar believes advancing to higher doses will increase the chance of success in achieving the longer-term goal to commercialize VAL-083 as a new chemotherapy for glioblastoma patients who have failed, or are unlikely to respond, to currently available treatments.

- DelMar presented new non-clinical research supporting the potential utility of VAL-083 in the treatment of non-small cell lung cancer at AACR in April.

- DelMar received an additional CDN $194,000 nonrefundable funding contribution from that National Research Council of Canada (NRC). Four non-dilutive funding contributions to date from NRC total CDN $327,000 and will be used to support continued non-clinical research aimed at providing competitive differentiation for VAL-083 as a new medicine in the treatment of glioblastoma and other cancers, including non-small cell lung cancer.

- DelMar received gross proceeds of $2,373,937 from the exercise of warrants at $0.65 per warrant that closed on June 6 and an additional $495,448 in gross proceeds from exercise of these warrants under the tender offer which closed on August 8. The exercise of warrants through a private transaction with certain warrant holders and subsequent tender offer has provided the company with additional non-dilutive capital, which the company believes will be sufficient to fund current operations through at least the end of December 2015.

Jeffrey Bacha, president & CEO of DelMar Pharmaceuticals stated, "We are pleased with the overall progress made during the past year in research and development activities. The warrant tender offer and change in our fiscal year end are part of our overall strategy to meet the requirements to list our common stock on a national securities exchange in the most expeditious manner possible. We believe is an important component of executing on our overall mission to increase shareholder value."

The following tables represent selected financial information as at June 30, 2014 and December 31, 2013. The company's financial information has been prepared in accordance with US GAAP and this selected information should be read in conjunction with DelMar's financial statements and Management's Discussion and Analysis, as filed.

Selected Balance Sheet Data:

                                                            June 30,   December 31, 

                                                               2014            2013

                                                               	  $               $



                       Cash and cash equivalents	   4,759,711       4,136,803

                                Working capital		   4,704,044	   4,069,261

                                 Total Assets		   5,003,910	   4,318,748

                            Derivative liability	   3,329,367	   4,402,306

         Total shareholders' equity (deficiency)	     880,479	    (817,978)



Selected Statement of Operations Data (net of share-based payments):

		                                                 Six Months ended

		                                              June 30,       June 30, 

                                                                  2014           2014

                                                                     $              $



 Research & development net of share-based compensation 	848,335	       907,223

General & administrative net of share-based compensation      1,007,781      1,363,406

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

VAL-083 Phase I/II VAL-083 clinical trial advances to 50mg/m2 cohort Company raises an additional $2.9 million in non-dilutive financing through warrant exercise

Vancouver, BC -- (SBWIRE) -- 08/19/2014 -- DelMar Pharmaceuticals, Inc.(OTCQB: DMPI) ("DelMar" "the company") announced today a protocol amendment to allow for expanded dosing in its VAL-083 clinical trial had been filed with the U.S. Food and Drug Administration (FDA) and that a new cohort of a new 50mg/m2 has been opened at three clinical trial sites in the United States. The company also confirmed that gross proceeds of US$2.9 million have been raised through warrant exercise in two separate closings. These funds provide sufficient working capital to fund DelMar's current operations, including its glioblastoma clinical trial, through at least December 2015.

One of three glioblastoma multiforme (GBM) patients in the most recent (40mg/m2) cohort and one of three GBM patients in the previous (30mg/m2) cohort exhibited stable disease after one or two cycles of treatment with VAL-083. No drug-related serious adverse events or dose limiting toxicities (DLTs) have been detected and a maximum tolerated dose (MTD) has not been reached at doses up to 40 mg/m2.

The company plans to present detailed results at scientific meetings during the second half of 2014.

Jeffrey Bacha, president and CEO of DelMar stated, "Patients being enrolled in our current clinical trial have a growing brain tumor that has failed to respond to any other approved treatment. The correlation between tumor progression and death in this patient population is well documented; therefore, our interim results demonstrating that, in some patients at doses studied to date, VAL-083 can either stabilize disease progression by halting tumor growth (as measured by RANO criteria) or shrink the tumor is expected to result in longer patient survival and improved quality of life. We anticipate enhanced response rates as we progress to higher doses and keep patients on treatment longer during future registration-directed clinical trials."

Avoiding Chemotherapy Resistance: VAL-083 MOA Is Unaffected by MGMT Expression

VAL-083 is a first-in-class small molecule chemotherapy that was studied in previous clinical trials sponsored by the U.S. National Cancer Institutes (NCI). In NCI-sponsored clinical trials, VAL-083 demonstrated activity against a range of tumor types, including GBM. DelMar's data suggest that the tumor-killing mechanism of VAL-083 is distinct from other chemotherapies approved for the treatment of GBM and therefore are not subject to resistance by mechanisms such as MGMT, which are believed to cause the majority of patients to fail chemotherapies available for treatment today.

DelMar first presented data demonstrating the activity of VAL-083 against patient-derived MGMT-expressing tumors that are resistant to other chemotherapies approved for the treatment of GBM at the 2012 Annual Meeting of the American Association of Cancer Research (AACR). Details of the company's scientific presentations can be found at:http://www.delmarpharma.com/products/publications/

Improved Safety and Tolerability Profile of VAL-083 Allows for Higher Dosing

DelMar previously announced that the company had received a notice of allowance from the FDA enabling the company to implement a more rapid dose-escalation scheme in our GBM study. The revised dosing regimen was allowed by the FDA following an extensive safety review of patients treated prior to that date. This latest protocol amendment, which is based on analysis of the safety and tolerability of VAL-083 delivered under DelMar's modernized dosing regimen, allows dosing at higher doses than originally anticipated.

Mr. Bacha added, "The use of many cancer drugs is limited by toxicity and a narrow therapeutic window. We are pleased that the hypothesis behind our modernized dosing regimen appears to be achieving an improved systemic safety profile while at the same time delivering substantially higher doses of VAL-083 compared to previous clinical trials sponsored by the U.S. National Cancer Institutes and other international studies."

Dose Escalation  Patients Treated   Status                 Cumulative dose in 33-day cycle

Scheme(mg/m2)                                                (comparison to NCI historical

	     	        	                              regimen of 125mg/m2 per cycle)                                                                                                                       

Original Revised* 			

1.5	  1.5	        3	    Completed – No DLT	                 9 mg/m2

3.0	  3.0	        4**	    Completed – No DLT	                 18 mg/m2

5.0	  5.0	        10**	    Completed – No DLT	                 30 mg/m2

10.0	  10.0	        3	    Completed – No DLT	                 60 mg/m2

15.0	  20.0	        3	    Completed – No DLT	                 120 mg/m2

20.0				

25.0	  30.0	        3	    Completed – No DLT	                 180 mg/m2

30.0				

40.0	  40.0	        3	    Completed – No DLT	                 240 mg/m2

na	  50.0	        3 (planned) Enrollment Ongoing	                 300 mg/m2

na	  60.0	        3 (planned) To be initiated subject to           360 mg/m2

                                    evaluation of 50mg/m2 dose	

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm